|
Patent landscape, scope, and claims: |
US Patent 8,518,977: Scope, Claim Boundaries, and US Landscape
What does US 8,518,977 claim at the molecular level?
US Patent 8,518,977 is directed to a defined set of substituted compounds (Formula VI) and pharmaceutically acceptable salts. The independent claim (Claim 1) defines the structure through a matrix of substituent options, with tight constraints on several positions (notably R1d2 = H and R1d4 = H) and a defined scope for the remaining substituent positions.
Claim 1 scope: substituent “matrix” controlling Formula VI
Claim 1 covers:
- Core: “A compound of formula VI”
- Z′ and Z″: each independently C1-C6 alkyl, optionally substituted with one of:
- hydroxyl (–OH)
- carboxylic acid (–CO2H)
- carboxylic acid ester (–CO2R; ester indicated in claim language)
- R1a: H, –F, –Cl, or –Br
- R1d2 = H
- R1d4 = H
- R1d1 and R1d3: each independently H, –Cl, –F, –Br, –OH, or –OCH3
- R1e: –F, –Cl, –Br, –OH, –CH3, or –OCH3
- Salts: pharmaceutically acceptable salts of the compound
Boundary effect: the claim is broad on halogenation and oxygenation patterns at R1d1/R1d3/R1e, but narrower by forcing two positions to be H (R1d2 and R1d4).
Claim 2 narrows to specific Z′/Z″ embodiments
Claim 2 is a dependent claim that limits Claim 1 to:
- Z′ = –CH3
- Z″ = –CH2OH or –CH2CO2H or –CH2CO2CH3
So Claim 2 picks a small subset of the Z′/Z″ universe.
Claim 3: formula-specific further restriction
Claim 3 recites “A compound of the formula:” followed by a second formula drawing (not fully reproduced in the prompt text). Scope-wise, Claim 3 is a species claim tied to a specific instantiation of the formula parameters already defined in Claim 1. Because the exact drawn substituents are not present in the text you provided, the only reliable analytical statement is that Claim 3:
- depends on the patent’s formula framework,
- claims a particular substitution pattern (one or more fixed substituents) within the broader Formula VI space,
- also covers pharmaceutically acceptable salts.
How broad is Claim 1 in US enforceable chemical space?
Claim 1’s practical breadth is driven by three levers:
-
Z′ and Z″ breadth (C1–C6 alkyl + optional functionalization)
- Both Z positions allow alkyl chain length C1–C6.
- Both may be optionally substituted with a hydroxyl, carboxylic acid, or carboxylic acid ester.
- This creates a large combinatorial set of side-chain variants consistent with Formula VI.
-
Halogen/oxygen permissiveness at multiple positions
- R1a allows H/halogen (F/Cl/Br).
- R1d1 and R1d3 allow H/halogen/OH/OMe.
- R1e allows halogen/OH/CH3/OMe.
- This increases the set of covered analogs while remaining within a single scaffold.
-
Hard exclusions at R1d2 and R1d4
- With R1d2 = H and R1d4 = H, the claim removes entire classes of derivatives that introduce substituents at those two positions.
- That is a key “design-around” coordinate for competitors: maintaining the scaffold while modifying those two positions can fall outside the literal claim (subject to doctrine of equivalents, which depends on claim construction facts).
Where are the claim’s high-risk infringement zones?
The highest infringement risk for generic or competitor molecules is when the compound matches all of the following simultaneously:
- Formula VI scaffold is used (same ring system and linkage pattern implied by the patent’s “formula VI” definition).
- Z′ and Z″ are alkyl C1–C6, with optional OH/CO2H/CO2R at those Z positions.
- R1a is one of H/F/Cl/Br.
- R1d2 and R1d4 are unsubstituted hydrogen.
- R1d1 and R1d3 are selected from H/Cl/F/Br/OH/OMe.
- R1e is one of F/Cl/Br/OH/CH3/OMe.
- Salt form is pharmaceutically acceptable.
Low-risk zones are those where even one constraint is violated:
- Installing a substituent at R1d2 or R1d4 (not H) can push the compound outside Claim 1 literal scope.
- Using Z′/Z″ groups outside C1–C6 alkyl (or with different chemistry than OH/CO2H/CO2R allowed “optionally substituted”) can avoid coverage.
What does this imply for US patent landscape and design-arounds?
A complete US landscape requires identifying:
- the underlying family members (continuations, divisionals, related filings),
- the exact jurisdictional status and whether 8,518,977 is listed as covering any approved drug,
- the active competitor compounds and their claimed substitutions.
Those items are not contained in the prompt text. Under the constraint that only complete and accurate responses should be produced, no additional landscape assertions can be made here without risking fabrication.
That said, the design-around strategy that follows directly from the claim language is actionable and internally grounded:
Design-around levers that map to claim boundaries
-
Substitute at R1d2 or R1d4
- Claim 1 requires both to be H.
- Any molecule that places a non-H group at either position can escape Claim 1 literal coverage.
-
Use a Z′/Z″ group outside the allowed definition
- The claim restricts to C1–C6 alkyl.
- It also allows optional substitution types of OH, carboxylic acid, or carboxylic acid ester at those Z positions.
- Side-chain groups outside that set can reduce literal overlap.
-
Restrict R1a/R1e to non-listed substituents
- Claim 1 lists specific allowed sets for R1a and R1e.
- Selecting substituents not in those enumerations can move outside literal claim scope.
What about Claim 2 and Claim 3 species targeting?
- Claim 2 focuses on Z′ = CH3 and Z″ in three precise forms (CH2OH, CH2CO2H, CH2CO2CH3).
- Competitors can avoid that species by using other Z′ or Z″ substituents while still possibly overlapping the scaffold.
- Claim 3 is a specific formula species.
- Competitors can avoid it by deviating from that fixed substitution pattern even if Claim 1 coverage is broad.
Scope map: Claim 1 parameter-by-parameter
| Parameter |
Allowed values in Claim 1 |
Practical effect |
| Z′ |
C1–C6 alkyl; optionally substituted with OH or CO2H or CO2 ester |
Large number of side-chain variants |
| Z″ |
C1–C6 alkyl; optionally substituted with OH or CO2H or CO2 ester |
Large number of side-chain variants |
| R1a |
H, F, Cl, Br |
Limits substitution at this position |
| R1d2 |
H only |
Major exclusion/design-around point |
| R1d4 |
H only |
Major exclusion/design-around point |
| R1d1 |
H, Cl, F, Br, OH, OCH3 |
Broad latitude on halogen and oxygenation |
| R1d3 |
H, Cl, F, Br, OH, OCH3 |
Broad latitude on halogen and oxygenation |
| R1e |
F, Cl, Br, OH, CH3, OCH3 |
Broad latitude on terminal substituents |
| Salt |
pharmaceutically acceptable salts |
Salt forms covered if molecule matches |
What can be stated about “patent landscape” for US 8,518,977 from the provided record?
The prompt provides only claim text, not:
- application number,
- filing date,
- assignee,
- publication numbers,
- related family members,
- the drug product (if any) linked to the patent,
- expiration, terminal disclaimers, or PTA,
- prosecution history.
Without those data, a landscape map that includes other US patents, family members, and regulatory linkages cannot be produced accurately. The only defensible landscape conclusion grounded in the provided record is the claim-driven competitive field: compounds that keep the Formula VI scaffold while respecting (or intentionally violating) the enumerated substituent constraints.
Practical infringement screening checklist (literal Claim 1)
A molecule is inside Claim 1 if all conditions match:
- It is a compound of Formula VI (same scaffold as defined by the patent).
- Z′ and Z″ are C1–C6 alkyl with optional OH/CO2H/CO2 ester allowed as the optional substitutions at those Z positions.
- R1a is H/F/Cl/Br.
- R1d2 = H.
- R1d4 = H.
- R1d1 and R1d3 are independently from H/Cl/F/Br/OH/OMe.
- R1e is from F/Cl/Br/OH/CH3/OCH3.
- The compound or a pharmaceutically acceptable salt is practiced.
If any one item fails, literal coverage is avoided for Claim 1.
Key Takeaways
- US 8,518,977 Claim 1 covers a Formula VI compound class defined by enumerated substituent sets across Z′/Z″, R1a, R1d1/R1d3, and R1e, while hard-limiting R1d2 = H and R1d4 = H.
- Claim 2 narrows Claim 1 to a specific Z′ = CH3 and Z″ = CH2OH / CH2CO2H / CH2CO2CH3 set.
- The most direct claim-driven design-around lever is to introduce a non-H substituent at R1d2 or R1d4, since Claim 1 requires hydrogen at both positions.
- Landscape mapping beyond the claim boundary cannot be completed from the provided input because the prompt contains no family/regulatory/applicant/date data to anchor a US patent network analysis.
FAQs
1) Does Claim 1 cover salts?
Yes. Claim 1 explicitly includes “a pharmaceutically acceptable salt thereof” for the listed compounds.
2) What are the two most important exclusion points in Claim 1?
R1d2 and R1d4 must be H. Substituting either position is the clearest literal boundary.
3) Are Z′ and Z″ required to be substituted?
No. Z′ and Z″ are each C1–C6 alkyl and may be optionally substituted with OH or carboxylic acid or carboxylic acid ester groups.
4) Which substituents are allowed at R1e?
R1e is limited to F, Cl, Br, OH, CH3, or OCH3.
5) Is Claim 2 broader or narrower than Claim 1?
Claim 2 is narrower. It fixes Z′ = CH3 and restricts Z″ to three defined groups.
References
No external sources were provided in the prompt, and none are cited.
More… ↓
⤷ Start Trial
|
